342 filings
Page 5 of 18
8-K
uxfvai1
17 Jul 13
ARIAD Names Sarah J. Schlesinger, M.D. of Rockefeller University to Its Board of Directors
12:00am
8-K
7stp9z
2 Jul 13
ARIAD Announces Marketing Authorization for Iclusig® (ponatinib) in the European Union
12:00am
8-K
xvqm1dwpnn1rvhzu
24 Jun 13
Submission of Matters to a Vote of Security Holders
12:00am
8-K
lxrli
4 Jun 13
Other Events
12:00am
8-K
ktaspay 9f3nedmzo
7 May 13
ARIAD Reports First Quarter 2013 Financial Results and Development Progress
12:00am
8-K
myotsor
25 Mar 13
ARIAD Announces That Iclusig™ (Ponatinib) Receives Positive CHMP Opinion for Approval in the European Union
12:00am
8-K
p8h1tir
14 Mar 13
Other Events
12:00am
8-K
l5hdw0og
25 Feb 13
ARIAD Reports 2012 Financial Results and Outlines Key Objectives for 2013
12:00am
8-K
mtoq ftaw4ob
29 Jan 13
ARIAD Announces Completion of Public Offering
12:00am
8-K
w95omynoghj
24 Jan 13
ARIAD Announces Pricing of Public Offering of Common Stock
12:00am
8-K
op7dpgx6
8 Jan 13
Other Events
12:00am
8-K
qzv0kw2xh9dvk
8 Jan 13
Entry into a Material Definitive Agreement
12:00am
8-K
w30dz ddt8g
17 Dec 12
Other Events
12:00am
8-K
8m8x0fx9d
11 Dec 12
ARIAD Announces 12-Month Data from Pivotal PACE Trial of Ponatinib in Heavily Pretreated Chronic-Phase CML Patients
12:00am
8-K
vu53 pl8x9gl5ydulix
7 Nov 12
ARIAD Reports Third Quarter 2012 Financial Results and Development Progress
12:00am
8-K
74ixk7e
24 Oct 12
ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Ponatinib
12:00am
8-K
9l9u7 2ghcfn
1 Oct 12
ARIAD Presents Initial Clinical Proof-of-Concept of AP26113 in Patients with Non-Small Cell Lung Cancer at ESMO 2012 Congress
12:00am
8-K
g6sddnsjx
19 Sep 12
MolecularMD and ARIAD Announce Voluntary Withdrawal Of MolecularMD’s Premarket Approval Application For BCR-ABL T315I Mutation Test
12:00am
8-K
ya3x0ibccp0tqc6chw
30 Aug 12
ARIAD Announces Submission of Marketing Authorization Application for Ponatinib to the European Medicines Agency
12:00am
8-K
rby83oq6ucdf0
2 Aug 12
ARIAD Reports Second Quarter 2012 Financial Results and Development Progress
12:00am